GlassScriptPhysician profile
Mhd Hamshow
NPI 1841032927
$479.25
in general payments reported to CMS, 2019-2025
11 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $50.09 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $143.04 | 2025 | Fasenra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.98 | 2025 | Xifaxan |
| Averitas Pharma INC. | $47.31 | 2025 | Qutenza |
| Janssen Biotech, INC. | $32.77 | 2025 | Tremfya |
| Kestra Medical Technology Services, INC. | $23.74 | 2024 | Assure Wcd |
| Lilly USA, LLC | $21.94 | 2025 | Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.72 | 2025 | Lifevest |
| Tolmar, INC. | $19.20 | 2025 | Rubraca |
| Pharmaand Gmbh | $19.20 | 2025 | Rubraca |
| Recor Medical INC | $17.35 | 2024 | Paradise Renal Denervation System |
| Dynavax Technologies Corporation | $9.00 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mhd Hamshow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.